SavedAdd your journal

Journals / Hacettepe Journal of Biology and Chemistry / 2018 / Cilt: 46 - Sayı: 3

Cytotoxic Activity of Apixaban on HeLa Cells: An In vitro Study

Özer Aylin GÜRPINAR
Emre KUBAT
Mehmet Ali ONUR
Pages
395–402
Publication Date
2018-09-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

These results show that apixaban may reduce proliferation of cancer cells at high concentrations.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Apixaban is a new oral anticoagulant which is commonly used in the prophylaxis and treatment of systemic embolism and deep vein thrombosis.
📊
Key Findings & Data:The viability of HeLa cells was examined at 24 and 48 hours of incubation and apixaban showed a cytotoxic effect in the highest dilution.
💡
Conclusion & Impact:These results show that apixaban may reduce proliferation of cancer cells at high concentrations.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Apixaban · new oral anticoagulant · venous thromboembolism

Abstract

Apixaban is a new oral anticoagulant which is commonly used in the prophylaxis and treatment of systemic embolism and deep vein thrombosis. Venous thromboembolic events are important risk factors in cancer patients. Several studies have suggested that anticoagulant drugs may have an effect on tumor development and progression. In this study, we aimed to investigate the cytotoxic effect of apixaban on a cancer cell line HeLa cells derived from human cervical cancer. The viability of HeLa cells was examined at 24 and 48 hours of incubation and apixaban showed a cytotoxic effect in the highest dilution. In other dilutions, cell viability was similar to the control group. These results show that apixaban may reduce proliferation of cancer cells at high concentrations.

🔖

Cite This Article

GÜRPINAR, Ö. A., KUBAT, E., ONUR, M. A. (2018). Cytotoxic Activity of Apixaban on HeLa Cells: An In vitro Study. Hacettepe Journal of Biology and Chemistry, Cilt: 46 - Sayı: 3, 395–402. https://ajindex.com/articles/255834

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. A. Di Minno, B Frigerio, G. Spadarella, A. Ravani, D. Sansaro, M. Amato, J.P. Kitzmiller, M. Pepi, E. Tremoli, D. Baldassarre, Old and new oral anticoagulants: Food, herbal medicines and drug interactions. Blood. Rev., 31 (2015) 193-203.
  2. C. Frost, J. Wang, S.Nepal, A. Schuster, Y.C. Barrett, R. Mosqueda-Garcia, R.A. Reeves, F. LaCreta, Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. BJCP. 75 (2012) 476-487.
  3. G.T. Gerotziafas, I. Mahé, I. Elalamy, New orally active anticoagulant agents for the prevention and treatment of venous thromboembolism in cancer patients. Ther. Clin. Risk. Manag., 10 (2014) 423-426
  4. A. Di Minno, B Frigerio, G. Spadarella, A. Ravani, D. Sansaro, M. Amato, J.P. Kitzmiller, M. Pepi, E. Tremoli, D. Baldassarre, Old and new oral anticoagulants: Food, herbal medicines and drug interactions. Blood. Rev., 31 (2015) 193-203.
  5. C. Frost, J. Wang, S.Nepal, A. Schuster, Y.C. Barrett, R. Mosqueda-Garcia, R.A. Reeves, F. LaCreta, Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. BJCP. 75 (2012) 476-487.
  6. G.T. Gerotziafas, I. Mahé, I. Elalamy, New orally active anticoagulant agents for the prevention and treatment of venous thromboembolism in cancer patients. Ther. Clin. Risk. Manag., 10 (2014) 423-426. Ö.A. Gürpınar et al. / Hacettepe J. Biol. & Chem., 2018, 46 (3), 395–402 401 V. Der Hulle, P.L. Den Exter, J. Kooiman, J.J.M. Van der Hoeven, M.V. Heismen, F.A. Klok, Meta-analysis of the efficacy and safety of new oral anticoagulants in patients with cancer-associated acute venous thromboembolism. J. Thromb. Haemost., 12 (2014) 1116-1120.
  7. M.N. Levine, C. Gu, H.A. Liebman, C.P. Escalante, S. Solymass, D. Deitchman, L. Ramirez, J. Julian, A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. J. Thromb. Haemost., 10 (2012) 807-814.
  8. L. Guasti, A. Sqizzato, P. Moretto, D., Vigetti, W. Agero, F. Dentali, A.M. Moresca, L. Campiotti, A.M. Grandi, A. Passi, In vitro effects of Apixaban on 5 different cancer cell lines. PlosOne, 12 (2017) 1-19.
  9. T.A. Hambrough, G.M. Swartz, A. Papathanassiu, G.P. Vlasuk, W.E. Rote, S.J. Green, V.S. Pribluda, Tissue Factor/Factor VIIa Inhibitors Block Angiogenesis and Tumor Growth Through a Nonhemostatic Mechanism. Cancer Res., 63 (2003) 2997-3000.
  10. J. Ferlay, I. Soerjomataram, R. Dikshit, S. Ese